Global Multiple Myeloma Therapeutics Market and Forecast to 2030

Apelo Consulting has released a report on “Global Multiple Myeloma Therapeutics Market (By Disease, Treatment, Route of Administration, End User, Regional Analysis), Company Profiles, Market Dynamics and Recent Developments – Forecast to 2030”

1. 2024-2030
Comprehensive Market Overview | Growth Drivers | Segmentation | Regional
Insights | Future Outlook
Prepared by Apelo Consulting
1
Global Multiple Myeloma Therapeutics Market Analysis Apelo Consulting
Global Multiple Myeloma
Therapeutics Market Analysis

2. Market size: USD 27,013M (2024) → USD 39,084M (2030)
CAGR (2024–2030): ≈ 6.3%
Key Growth Drivers:
Rising prevalence and aging population
Improved diagnostic criteria
Adoption of targeted therapies
Increasing awareness and early detection
2024 Market Leaders:
Disease: Active Multiple Myeloma
Treatment: Targeted Therapy
Administration: Oral Route
End User: Hospitals
Region: North America
Apelo Consulting | Page 2Executive Summary

3. Multiple Myeloma: Cancer characterized by uncontrolled
proliferation of clonal plasma cells, leading to organ
dysfunction and eventually death
Treatment Landscape:
Chemotherapy: Targets rapidly dividing cancer cells
throughout the body
Targeted Therapy: Proteasome inhibitors and
monoclonal antibodies - less toxic alternatives
Immunomodulating Agents: Thalidomide, lenalidomide,
pomalidomide
Radiation Therapy: Manages localized bone lesions,
alleviates pain
Stem Cell Transplantation: For eligible patients, after
induction
Apelo Consulting | Page 3Market Overview & Disease Profile
Market Focus: Early diagnosis and tailored treatments are
crucial for enhancing patient outcomes and increasing
survival rates
36,110
New cases expected in the U.S. (2025)
Source: National Cancer Institute

4. Apelo Consulting | Page 4Segmentation by Disease Type
Early intervention in SMM cases has shown promising results
in delaying progression to active MM, driving increased focus
on detection technologies and preventive therapies.
Market position: Dominant segment
Characteristics: Symptomatic, requires immediate
treatment
Growth drivers: Advancements in supportive care,
combination therapies
Treatment focus: Disease management, extending
remission periods
Active Multiple Myeloma
Market position: Smaller but growing segment
Characteristics: Asymptomatic, higher levels of abnormal
plasma cells
Growth trend: Early detection increasing due to improved
diagnostics
Treatment approach: Monitoring with timely intervention
before symptom development
Smoldering Multiple Myeloma (SMM)

5. Targeted Therapy: Dominant segment in 2024, offering
more effective and less toxic alternatives to traditional
chemotherapy
Chemotherapy: Maintained over 25% market share in
2024, remains foundational for systemic treatment
Immunomodulating Agents: Core components for
frontline and maintenance therapy, known for oral
convenience
Stem Cell Transplantation: Critical for eligible patients,
typically performed after induction therapy
Radiation Therapy: Focused on symptom management
for bone lesions rather than primary treatment
Others: Supportive care and adjunct approaches
complement mainstream therapies
Apelo Consulting | Page 5Treatment Landscape Segmentation

6. Route of Administration
Apelo Consulting | Page 6Route of Administration & End User
*Oral administration continues to gain preference due to
improved patient compliance and convenience factors
Oral Route: Dominant; non-invasive approach
offering better adherence, convenience, and
reduced hospital visits
Parenteral Route: Critical for
advanced/refractory cases; allows precise
dosing and clinical monitoring
Hospitals: Leading segment; equipped with
advanced infrastructure for complex treatment
protocols
Clinics: Provide specialized outpatient care in
more accessible settings
Homecare: Growing segment for maintenance
therapies and oral regimens
End User

7. North America: Dominant market position
Advanced healthcare infrastructure, high disease
prevalence, rapid integration of innovative therapies
Europe: Second largest market
Strong uptake of targeted therapies and personalized
medicine across Germany, UK, France, and Italy
Asia Pacific: Emerging market
Increasing healthcare expenditure, rising awareness, and
improving healthcare infrastructure
Latin America: Developing market
Expanding access to novel therapies and treatment
options
Middle East & Africa: Growth potential
Improving care pathways and increasing investment in
healthcare
Apelo Consulting | Page 7
Regional Market Analysis

8. Leading pharmaceutical companies and research institutions in the Multiple Myeloma therapeutics landscape
Apelo Consulting | Page 8
Key Market Players

9. Growth Drivers
Apelo Consulting | Page 9Market Dynamics: Drivers & Challenges
Rising Prevalence & Aging Demographics
Increasing incidence rates globally, particularly in
aging populations with 36,110 new US cases
expected in 2025
Improved Diagnostic Criteria & Earlier Detection
Enhanced screening methods and diagnostic
technologies enabling earlier disease identification,
especially for SMM
Advancements in Targeted Therapies
Revolutionary treatment options including
proteasome inhibitors and monoclonal antibodies
with higher efficacy and lower toxicity
Growing Awareness & Screening Practices
Increased knowledge among healthcare providers
and patients leading to improved care pathways
and treatment adherence
Challenges
High Treatment Costs & Access Disparities
Novel therapies and combination regimens
associated with substantial costs, creating barriers
to access particularly in developing regions
Complex Disease Management
Requirement for specialized multidisciplinary care
teams and individualized treatment approaches
Treatment Resistance & Relapse
Development of resistance to therapy over time,
necessitating multiple lines of treatment and
ongoing research
Need for Specialized Healthcare Infrastructure
Advanced treatment modalities require
sophisticated healthcare systems and trained
professionals

10. Market Growth: USD 27.0B (2024) to USD 39.1B (2030); ~6.3% CAGR driven
by increasing prevalence and advanced therapies
Disease Segments: Active MM remains dominant; Smoldering MM
detection rising with improved diagnostic criteria and earlier
intervention
Treatment Landscape: Targeted therapies and IMiDs anchor treatment
growth; chemotherapy retains significant role (25%+ market share)
Administration & Settings: Oral route dominates administration;
hospital settings lead utilization patterns due to infrastructure
advantages
Regional Dynamics: North America leads market; Asia Pacific offers
highest growth runway with increasing healthcare expenditure
Future Innovation: Novel molecular targets, combination regimens, and
personalized medicine approaches will shape market evolution
Apelo Consulting | Page 10
Key Takeaways & Market Outlook
Continued innovation in targeted therapies paired with broader market access will be critical
success factors for stakeholders in this growing therapeutic area.

11. THANK YOU www.apeloconsulting.com